Objective-To assess the effectiveness of a two tier neonatal screening strategy for cystic fibrosis, which combines estimation of immunoreactive trypsinogen foliowed by direct gene analysis in dried blood spot samples coilected at age 5 days.
Design-Prospective study of two tier screening strategy. The first tier of testing immunoreactive trypsinogen concentration was measured in dried blood spot samples from neonates aged [4] [5] analysis for screening is that there are too many cystic fibrosis mutations to be included in a cost effective screen. The initial estimation of immunoreactive trypsinogen concentration must therefore remain the initial screening criterion, with specificity and sensitivity being achieved by subsequent testing for the most common cystic fibrosis mutations in selected subjects.
A successful neonatal screen for cystic fibrosis on this basis has been operating in South Australia since December 1989. The results of the first six months of this programme reported here are the first to show the practical viability of the proposed strategy and its advantages over those used previously.
Materials and methods
Blood spot specimens-Specimens to be screened were dried blood spots (Guthrie cards) routinely collected as part of a wider programme of screening 5 day old neonates for hypothyroidism, galactosaemia, and phenylketonuria in South Australia and Tasmania. Apart from standard identification and birth weight data, the presence or suspicion of meconium ileus in any infant is additional information required by the screening laboratory.
Estimation (DELFIA system, Pharmacia (Australia) Sydney, New South Wales, Australia). The change of immunoassay label from enzyme to europium significantly improved the interassay precision to a coefficient of variation of 7-2% around the decision value (78 [tg trypsin/l whole blood), resulting in less variability in the upper centiles of the population distribution of neonatal immunoreactive trypsinogen values.
Direct gene analysis-Discs of 3 mm diameter punched from the dried blood spot samples were placed directly into polymerase chain reaction buffer at 4°C and left overnight. Amplification of DNA and detection of cystic fibrosis alleles were performed according to published techniques."
Sweat testing-Sweat testing of infants was performed using pilocarpine iontophoresis, as originally described. 16 Screening strategy- Figure 1 shows the neonatal screening strategy for cystic fibrosis. An immunoreactive trypsinogen concentration of 78 [tg trypsin/l whole blood (equal to the 99th centile for the unpartitioned neonatal population) was of whom had meconium ileus at birth. Thirteen infants (0-108%) were heterozygous for AF508 and were recalled for sweat testing, the results of which were available by the age of 4-5 weeks. In two (0-017%) of these infants cystic fibrosis was diagnosed on sweat testing, and they were referred for clinical management. Further investigations from the initial blood spot specimens excluded the cystic fibrosis mutations G542X, G551D, and R553X'4 in these infants. The families of the remaining 11 (0-091%) unaffected infants heterozygous for AF508 were also offered further counselling and gene analysis. In every case this offer was accepted without reluctance, and each couple was able to be advised of the risks to any future pregnancy.
The incidence of cystic fibrosis detected by this strategy to date is 1:2009 liveborn children. False negative results so far are unknown with complete certainty, but the observed detection rate compares well with the known population incidence of cystic fibrosis in South Australia (1:2200 live births). The specificity of the screening strategy is 35 3%, with 2-8 families being contacted for every case of cystic fibrosis detected. All families contacted carry at least one cystic fibrosis mutation.
Discussion
The advantages of neonatal screening and early diagnosis of cystic fibrosis to the longer term welfare of those affected are gradually becoming evident."-" A practical screening strategy of higher specificity and sensitivity than has so far been published is required before such screening is unreservedly accepted. ( 13) of the screened neonates were recalled for sweat testing. For this last group there was a 1 in 6-5 chance of a diagnosis of cystic fibrosis. Overall, 2-8 families were contacted for each case of cystic fibrosis detected. These results compare favourably with those from strategies based on measurement of immunoreactive trypsinogen concentration alone. 2 (1 In addition, the recalled families whose infants were found subsequently not to have cystic fibrosis were alerted to the fact that at least one parent carries a cystic fibrosis mutation. Counselling included discussion about the investigation of both parents for the presence of recognised cystic fibrosis mutations to define the risks to future pregnancies. In all cases this counselling and subsequent gene analysis was accepted keenly by the families, and any residual anxiety remaining from the screening strategy was thereby removed.
Two possible sources of false negative results exist in this strategy. Various authors report false negative results by initial immunoreactive trypsinogen assay,95 7 10 amounting to around 3 8% of confirmed cases.' A high analytical imprecision of about 15% coefficient of variation2 57 1'2 around the decision value may contribute appreciably to this. With this level of analytical imprecision proposed recall rates between 0-18% and 0-8% of neonates' are indistinguishable from each other. In this programme the advantages of time resolved fluorescence immunoassay22 were used to improve the precision of the estimation of immunoreactive trypsinogen concentration.
Direct gene analysis imparts a greatly increased specificity to the screening strategy. Samples from those infants in whom there is clinical suspicion of meconium ileus are taken to direct gene analysis. This removes a major source of false negative results from the immunoreactive trypsinogen screen. There is, however, a priori, a 1 in 14 probability of an individual having cystic fibrosis who has neither the AF508 nor the A1506 mutation. Inclusion of other cystic fibrosis mutations in the screening strategy will reduce this probability. To this end we have recently added the mutations G542X, G551D, and R553X'4 21 Results-Patients with recurrent ketoacidosis had had a median (range) of 28 episodes. One man died of a cerebral tumour but five of the surviving nine patients had not been admitted in the past two years, although diabetic control remained poor (median haemoglobin A1 concentration 14%). Seven patients had pure hypoglycaemic brittleness, and five had also had eight or more admissions with ketoacidosis (mixed brittleness). Two died of uraemia within a year after ascertainment and two others in hypoglycaemic coma seven and 12 years later. Brittle diabetes was in most cases related to a specific situation, usually unhappiness at home or school.
Conclusions-Brittle diabetes is often episodic and almost always related to stressful life circumstances. Once the underlying cause is removed it tends to improve. Recurrent hypoglycaemic brittleness of psychological origin has a poor prognosis.
Introduction
In 1977 one of us (RT) suggested a simple definition for a brittle diabetic patient: "the patient whose life is constantly disrupted by episodes of hyper-or hypoglycaemia, whatever their cause."' Little is known about the course of brittle diabetes. Most studies have been cross sectional and concentrated on highly selected groups who have reached a specialist centre only because of the strain they place on hospital resources and family stability. We tried to clarify the course by an almost complete 12 
